The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion

Mark H. Siegelman, Diana Stanescu, Pila Estess

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Leukocytes extravasate from the blood in response to physiologic or pathologic demands by means of complementary ligand interactions between leukocytes and endothelial cells. The multistep model of leukocyte extravasation involves an initial transient interaction ('rolling' adhesion), followed by secondary (firm) adhesion. We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. The mechanism for subsequent firm adhesion has not been elucidated. Here we demonstrate that the integrin VLA-4 is used in secondary adhesion after CD44-mediated primary adhesion of human and mouse T cells in vitro, and by mouse T cells in an in vivo model. We show that clonal cell lines and polyclonally activated normal T cells roll under physiologic shear forces on hyaluronate and require VCAM-1, but not ICAM-1, as ligand for subsequent firm adhesion. This firm adhesion is also VLA-4 dependent, as shown by antibody inhibition. Moreover, in vivo short-term homing experiments in a model dependent on CD44 and HA demonstrate that superantigen-activated T cells require VLA-4, but not LFA-1, for entry into an inflamed peritoneal site. Thus, extravasation of activated T cells initiated by CD44 binding to HA depends upon VLA4-mediated firm adhesion, which may explain the frequent association of these adhesion receptors with diverse chronic inflammatory processes.

Original languageEnglish (US)
Pages (from-to)683-691
Number of pages9
JournalJournal of Clinical Investigation
Volume105
Issue number5
StatePublished - Mar 2000

Fingerprint

Integrin alpha4beta1
Lymphocyte Function-Associated Antigen-1
T-Lymphocytes
Hyaluronic Acid
Leukocytes
Ligands
Superantigens
Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Integrins
Adhesives
Endothelial Cells
Inflammation
Cell Line
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. / Siegelman, Mark H.; Stanescu, Diana; Estess, Pila.

In: Journal of Clinical Investigation, Vol. 105, No. 5, 03.2000, p. 683-691.

Research output: Contribution to journalArticle

Siegelman, Mark H. ; Stanescu, Diana ; Estess, Pila. / The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. In: Journal of Clinical Investigation. 2000 ; Vol. 105, No. 5. pp. 683-691.
@article{14f297a87f8443c696f9a4bc3b24acde,
title = "The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion",
abstract = "Leukocytes extravasate from the blood in response to physiologic or pathologic demands by means of complementary ligand interactions between leukocytes and endothelial cells. The multistep model of leukocyte extravasation involves an initial transient interaction ('rolling' adhesion), followed by secondary (firm) adhesion. We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. The mechanism for subsequent firm adhesion has not been elucidated. Here we demonstrate that the integrin VLA-4 is used in secondary adhesion after CD44-mediated primary adhesion of human and mouse T cells in vitro, and by mouse T cells in an in vivo model. We show that clonal cell lines and polyclonally activated normal T cells roll under physiologic shear forces on hyaluronate and require VCAM-1, but not ICAM-1, as ligand for subsequent firm adhesion. This firm adhesion is also VLA-4 dependent, as shown by antibody inhibition. Moreover, in vivo short-term homing experiments in a model dependent on CD44 and HA demonstrate that superantigen-activated T cells require VLA-4, but not LFA-1, for entry into an inflamed peritoneal site. Thus, extravasation of activated T cells initiated by CD44 binding to HA depends upon VLA4-mediated firm adhesion, which may explain the frequent association of these adhesion receptors with diverse chronic inflammatory processes.",
author = "Siegelman, {Mark H.} and Diana Stanescu and Pila Estess",
year = "2000",
month = "3",
language = "English (US)",
volume = "105",
pages = "683--691",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion

AU - Siegelman, Mark H.

AU - Stanescu, Diana

AU - Estess, Pila

PY - 2000/3

Y1 - 2000/3

N2 - Leukocytes extravasate from the blood in response to physiologic or pathologic demands by means of complementary ligand interactions between leukocytes and endothelial cells. The multistep model of leukocyte extravasation involves an initial transient interaction ('rolling' adhesion), followed by secondary (firm) adhesion. We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. The mechanism for subsequent firm adhesion has not been elucidated. Here we demonstrate that the integrin VLA-4 is used in secondary adhesion after CD44-mediated primary adhesion of human and mouse T cells in vitro, and by mouse T cells in an in vivo model. We show that clonal cell lines and polyclonally activated normal T cells roll under physiologic shear forces on hyaluronate and require VCAM-1, but not ICAM-1, as ligand for subsequent firm adhesion. This firm adhesion is also VLA-4 dependent, as shown by antibody inhibition. Moreover, in vivo short-term homing experiments in a model dependent on CD44 and HA demonstrate that superantigen-activated T cells require VLA-4, but not LFA-1, for entry into an inflamed peritoneal site. Thus, extravasation of activated T cells initiated by CD44 binding to HA depends upon VLA4-mediated firm adhesion, which may explain the frequent association of these adhesion receptors with diverse chronic inflammatory processes.

AB - Leukocytes extravasate from the blood in response to physiologic or pathologic demands by means of complementary ligand interactions between leukocytes and endothelial cells. The multistep model of leukocyte extravasation involves an initial transient interaction ('rolling' adhesion), followed by secondary (firm) adhesion. We recently showed that binding of CD44 on activated T lymphocytes to endothelial hyaluronan (HA) mediates a primary adhesive interaction under shear stress, permitting extravasation at sites of inflammation. The mechanism for subsequent firm adhesion has not been elucidated. Here we demonstrate that the integrin VLA-4 is used in secondary adhesion after CD44-mediated primary adhesion of human and mouse T cells in vitro, and by mouse T cells in an in vivo model. We show that clonal cell lines and polyclonally activated normal T cells roll under physiologic shear forces on hyaluronate and require VCAM-1, but not ICAM-1, as ligand for subsequent firm adhesion. This firm adhesion is also VLA-4 dependent, as shown by antibody inhibition. Moreover, in vivo short-term homing experiments in a model dependent on CD44 and HA demonstrate that superantigen-activated T cells require VLA-4, but not LFA-1, for entry into an inflamed peritoneal site. Thus, extravasation of activated T cells initiated by CD44 binding to HA depends upon VLA4-mediated firm adhesion, which may explain the frequent association of these adhesion receptors with diverse chronic inflammatory processes.

UR - http://www.scopus.com/inward/record.url?scp=0034116088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034116088&partnerID=8YFLogxK

M3 - Article

VL - 105

SP - 683

EP - 691

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -